InvestorsHub Logo
Followers 864
Posts 27574
Boards Moderated 1
Alias Born 11/05/2010

Re: DOLLARLAND post# 10077

Saturday, 11/10/2012 10:32:10 AM

Saturday, November 10, 2012 10:32:10 AM

Post# of 11554
FCSC/OTCBB. DD sheet. 2 impact-videos at the end.



98,989,988 shares issued and outstanding of common stock, par value $0.001.
10/Q 8/14/12 http://ih.advfn.com/p.php?pid=nmona&article=53814416
96,278,253 shares issued and outstanding of common stock, par value $0.001.
10/Q 5/15/12 http://ih.advfn.com/p.php?pid=nmona&article=52427940


iHub/all PRs. http://ih.advfn.com/p.php?pid=news&symbol=NB%5EFCSC
WebSite. http://www.fibrocellscience.com/

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence

Differentiating into all the specialized cells.


Fact Sheet. PDF.
http://www.fibrocellscience.com/wp-content/uploads/2011/12/FibrocellScienceFactSheet.pdf
Investor Presentation, very nice. 8/9/12.
http://www.fibrocellscience.com/wp-content/uploads/2011/11/Investor-Presentation-August.pdf

10/25/12 FCSC Inducted into Prestigious World Technology Network
http://ih.advfn.com/p.php?pid=nmona&article=54688728
10/17/12 Gold Award for LAVIV™ from Prestigious 2012 Golden Bridge Awards Program
http://ih.advfn.com/p.php?pid=nmona&article=54573347
10/16/12 LAVIV™ Recognized in the Prestigious Wall Street Journal Technology Innovation Awards
http://ih.advfn.com/p.php?pid=nmona&article=54541393
10/8/12 $45 Million Private Placement and Enters Strategic Collaboration with Intrexon
http://ih.advfn.com/p.php?pid=nmona&article=54434255
7/16/12 Second Quarter 2012 LAVIV Order Information
http://ih.advfn.com/p.php?pid=nmona&article=53482034
7/16/12 Fibrocell Science. Completes $9.1 Million Capital Raise
http://ih.advfn.com/p.php?pid=nmona&article=53482035
6/8/12 Sell Majority Ownership Stake in Agera Laboratories for $0.85 Million
http://ih.advfn.com/p.php?pid=nmona&article=52705800
5/3/12 Fibrocell Science Technology Leads to Discovery of Two Rare Adult Stem Cell-Like Subpopulations in Human Skin
Purification and Expansion of These Cells May Yield Further Research Advances to Exploring Potential Personalized Regenerative Therapies for a Variety of Conditions
http://finance.yahoo.com/news/fibrocell-science-technology-leads-discovery-130000397.html

LAVIV FAQ.
http://mylaviv.com/faq/
The company’s first product on the market, LAVIV™ (azficel-T).


UCLA collaboration.
The principal goal of the autologous stem cell research field is to reprogram human (somatic) cells, such as human autologous fibroblasts, from a patient into non-embryonic pluripotent stem cells that can then be changed into different potentially useful cell-types, such as cells of the central nervous system (neurons), pancreas (beta islets) or heart (cardiomyocytes). These cells could be used either for basic research or re-implantation into the donor (autologous transfer). As they would be genetically identical to the patient, autologous stem cells could have the potential to treat the symptoms of specific diseases, such as Parkinson’s, diabetes and heart disease, without eliciting an immune response. Inducing most adult somatic cells to return to a pluripotent state is difficult. Dr. James Byrne has discovered a subpopulation of cells present in adult human fibroblasts that are easier to reprogram into pluripotent stem cells. Usage of this subpopulation of cells may facilitate the generation of safe and clinically useful isogenic patient-specific cell-types for use in this project.
http://www.fibrocellscience.com/rd/ucla-collaboration/
YouTube video by this link only.
http://youtu.be/SehXLATfWBE


FibroCell and China.
Fibrocell and Hefei Meifu Bio-Tech Limited Co. (Meifu) have formed a joint venture to develop and market autologous fibroblast cell therapies in Asia, excluding Japan.

Notably, women account for more than half of China’s estimated $15 billion in luxury sales in 2010 (McKinsey & Company), and China is home to 11 of the world’s 20 richest self-made women (Hurun Report). In addition, the average female luxury consumer in China spent 22% more in 2010 than she did in 2008; by 2020, China is expected to be the world’s largest luxury market.
http://www.fibrocellscience.com/about-us/joint-ventures/


The Promise of Fibroblasts.
¦Fibroblast cells are responsible for the production of collagen and other extra cellular matrix proteins.
¦The fibroblast cells in LAVIV™ are native to the recipient and recognized by the body’s immune system as “self”.
¦Potential applications extend beyond Dermatology.
http://www.fibrocellscience.com/rd/

Fibrocell Science has developed an innovative technology to isolate, purify, and regenerate a patient’s own fibroblast cells for re-injection.



Fibroblasts are cells that contribute to the formation of connective tissue fibers. Fibrocell's future scientific focus will be on regenerative medicine that leverages the direct and indirect therapeutic benefit of fibroblasts.



Watching that recent support.




Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.